S I Hajdu

University of Southern California, Los Angeles, CA, United States

Are you S I Hajdu?

Claim your profile

Publications (256)853.75 Total impact

  • Steven I. Hajdu
  • Steven I. Hajdu
    09/2014; DOI:10.1016/j.jasc.2014.05.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimsHistorically, nuclear staining of 10% of invasive tumor cells was used for ER positivity. In 2010, ASCO/CAP guidelines recommended the cut off value be changed to nuclear staining of 1%. This study will analyze the relationships between levels of ER expression and clinicopathological features and clinical outcomes, with an emphasis on the ER 1-10% subgroup. Methods and ResultsWe analyzed clinicopathological features in 5 subgroups based on ER expression levels in 1700 consecutive invasive breast cancer patients diagnosed and treated at our institution between 2000 and 2011. 24% of cases had ER expression <1%, 2% were ER1-10%, 5% were ER11-50%, 5% were ER51-70% and 64% were ER71-100%. We observed four subgroups of patient cohorts (ER <1%, ER1-10%, ER11-70% and ER71-100%) that were unique in Nottingham grade, nuclear grade, PR expression and disease-free survival. Of the 341 patients with follow-up data, we found no significant differences in pathologic features between patients in the ER11-50% and ER51-70% subgroups. Conclusion These data support the important role of ER in breast cancer, and the importance of accurate testing and quantitative reporting for ER. Tumors with ER 1-10% are not common, and further studies are needed to better understand this subgroup of breast cancer.This article is protected by copyright. All rights reserved.
    Histopathology 03/2014; 65(4). DOI:10.1111/his.12412 · 3.30 Impact Factor
  • Steven I Hajdu, Manjunath Vadmal
    [Show abstract] [Hide abstract]
    ABSTRACT: In the 3 decades from 1940 to 1970, the United States became the nucleus for research, diagnosis, and treatment of cancer. The discovery of anticancer drugs, and the clinical demonstration that chemotherapy and radiation can cure cancer and have the ability to prevent recurrence of cancer, were incontrovertibly the most remarkable groundbreaking events. Consequently, the trend of less surgery and more multimodality therapy began. The introduction of radioautography, mammography, ultrasonography, computed tomography, Papanicolaou smear, and other novel laboratory tests furthered early detection of cancer and refined accurate diagnosis. The unequivocal linking of lung cancer to cigarette smoking made medical history. The delineation of the potential role of oncogenes adduced new thoughts about oncogenesis and cancer prevention, and pathologists finalized the classification and nosology of tumors. Finally, it is worth noting that although more advances were made in the detection, diagnosis, and treatment of cancers than any other period in history, the overall mortality rate of patients with cancer remained high and unchanged. Cancer 2013. © 2013 American Cancer Society.
    Cancer 12/2013; 119(23). DOI:10.1002/cncr.28319 · 5.20 Impact Factor
  • Steven I. Hajdu
    01/2013; DOI:10.1016/j.jasc.2013.10.002
  • Manjunath S Vadmal, Steven I Hajdu
    Annals of clinical and laboratory science 01/2012; 42(3):346-8. · 0.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast-conserving therapy (BCT) is an accepted therapeutic option for most breast cancer patients. However, mastectomy is still performed in 30-50% of patients undergoing surgeries. There is increasing interest in preservation of the nipple and/or areola in hopes of achieving improved cosmetic and functional outcomes; however, the oncologic safety of nipple-areolar complex (NAC) preservation is a major concern. We sought to identify the predictive factors for NAC involvement in breast cancer patients. We analyzed the rates and types of NAC involvement by breast carcinoma, and its association with other clinicopathologic features of the tumors in 787 consecutive therapeutic mastectomies performed at our institution between 1997 and 2009. Among these, 75 cases (9.5%) demonstrated NAC involvement. Only 21 (28%) of 75 of cases with NAC involvement could be identified grossly by inspection of the surgical specimen (seven of these had been clinically identified). NAC involvement was most significantly associated with tumors located in all four quadrants (P<0.0001), tumors>5 cm in size (P=0.0014 for invasive carcinoma and P=0.0032 for in-situ carcinoma), grade 3 tumors (P=0.0192), tumors with higher nuclear grades (P=0.0184), and tumors with HER2 overexpression (P=0.0137). On the basis of our findings, we have developed a mathematical model that is based on the extent and location of the tumor, HER2 expression, and nuclear grade that predicts the probability of NAC involvement by breast cancer. This model may aid in preoperative planning in selecting appropriate surgical procedures based on an individual patient's relative risk of NAC involvement.
    Annals of Surgical Oncology 10/2011; 19(4):1174-80. DOI:10.1245/s10434-011-2107-3 · 3.94 Impact Factor
  • Source
    Steven I Hajdu
    [Show abstract] [Hide abstract]
    ABSTRACT: In the early 19th century, microscopy in pathology replaced gross descriptive pathology of the 18th century. Cells became known as the most important and distinct elements of benign and cancerous tissues. Thus, by the mid-1800s, a solid foundation had been laid for microscopy, and surgeons recognized that microscopic diagnosis by pathologists merited attention. In due course, preoperative microscopic diagnoses and classification of cancers in biopsy specimens were incorporated into choosing the most fitting surgical operation.
    Cancer 07/2011; 118(4):1155-68. DOI:10.1002/cncr.26320 · 5.20 Impact Factor
  • Source
    Steven I Hajdu
    [Show abstract] [Hide abstract]
    ABSTRACT: Events that took place in medicine during the 15th, 16th, and 17th centuries signaled the end of the Dark Ages. The Renaissance movement, spreading from Italy across Europe, ended the religious and public prohibitions that had prevented progress in medicine. Pioneer physicians and surgeons who gave their attention to discoveries in anatomy, physiology, and chemistry established the foundations for tumor pathology, surgical oncology, and medical oncology. This review is a summary of their accomplishments.
    Cancer 06/2011; 117(12):2811-20. DOI:10.1002/cncr.25825 · 5.20 Impact Factor
  • Steven I Hajdu
    Annals of clinical and laboratory science 01/2011; 41(2):201-6. · 0.84 Impact Factor
  • Steven I Hajdu
    Annals of clinical and laboratory science 01/2011; 41(1):97-101. · 0.84 Impact Factor
  • Source
    Steven I Hajdu
    [Show abstract] [Hide abstract]
    ABSTRACT: In the second half of the 19th century, most cancer patients were cared for by surgeons who exerted ascesis and limited their operations to 1 or 2 specific areas. To assist surgeons and other physicians in caring for their patients, pathologists described newly discovered entities, refined the microscopic classification of tumors, and introduced the grading of cancers. The discoveries of Rontgen and the Curies revolutionized the diagnosis and treatment of cancers. The search for the cause of cancers extended to infectious organisms, chemicals, and radioactive materials. The 50 years covered in this review formed the groundwork for the coordinated, specialized care of cancer patients at institutions dedicated to render the most promising treatment. Cancer 2012;118:4914-28. (C) 2012 American Cancer Society.
    Cancer 10/2010; 117(5):1097-102. DOI:10.1002/cncr.25553 · 4.90 Impact Factor
  • Source
    Steven I Hajdu
    [Show abstract] [Hide abstract]
    ABSTRACT: Antonio Benivieni, an Italian physician, Theophilus Boneti, a Swiss physician, and Giovanni Battista Mogagni, an Italian physician, pioneered postmortem examination for finding hidden causes of diseases. By correlating the results of their clinical and postmortem examinations, they established the foundation of anatomic pathology, clinical medicine, and oncology.
    Cancer 03/2010; 116(10):2493-8. DOI:10.1002/cncr.25000 · 4.90 Impact Factor
  • Steven I Hajdu, Manjunath S Vadmal
    Annals of clinical and laboratory science 01/2010; 40(2):178-81. · 0.84 Impact Factor
  • Steven I Hajdu, Gang He
    Annals of clinical and laboratory science 01/2010; 40(3):304-8. · 0.84 Impact Factor
  • Steven I Hajdu
    Annals of clinical and laboratory science 01/2010; 40(1):88-9. · 0.84 Impact Factor
  • Steven I Hajdu, Farbod Darvishian
    Annals of clinical and laboratory science 01/2010; 40(4):386-90. · 0.84 Impact Factor
  • Steven I Hajdu
    Annals of clinical and laboratory science 02/2009; 39(1):92-3. · 0.84 Impact Factor
  • Steven I Hajdu
    Annals of clinical and laboratory science 02/2009; 39(2):196-8. · 0.84 Impact Factor
  • Steven I Hajdu, Ping Tang
    Annals of clinical and laboratory science 01/2009; 39(4):413-5. · 0.84 Impact Factor

Publication Stats

8k Citations
853.75 Total Impact Points


  • 2010
    • University of Southern California
      • Department of Pathology
      Los Angeles, CA, United States
  • 2008
    • University of California, Los Angeles
      Los Angeles, California, United States
  • 2007
    • CUNY Graduate Center
      New York, New York, United States
  • 2006
    • University Center Rochester
      • Department of Pathology
      Rochester, Minnesota, United States
    • University of Rochester
      • Department of Pathology and Laboratory Medicine
      Rochester, NY, United States
  • 1985–2006
    • Cornell University
      • Department of Medicine
      Ithaca, New York, United States
  • 1974–1999
    • Memorial Sloan-Kettering Cancer Center
      • • Department of Surgery
      • • Department of Pathology
      • • Head and Neck Service
      New York City, NY, United States
  • 1997
    • University of Colorado Hospital
      • Department of Pathology
      Denver, Colorado, United States
  • 1975
    • Gracie Square Hospital, New York, NY
      New York City, New York, United States
  • 1971
    • Memorial Hospital, TN
      Chattanooga, Tennessee, United States